66336-42-3Relevant articles and documents
Assembly of tricyclic compounds that include the spiro[4.4]nonane subunit
Liu,Wu,Burnell
, p. 656 - 664 (1997)
Spiroannulation of ketals derived from unsaturated cyclohexenone derivatives by the Lewis acid-catalyzed reaction of l,2-bis((trimethylsilyl)oxy)cyclobutene 5 led to spiro[4.5]decene-diones 9 and 30. These were transformed into spiro[4.4]nonene derivatives 25 and 35/36 via similar sequences involving ozonolysis and aldol ring reclosure. Reduction of an annular double bond allowed facile closure of a third ring, also by an aldol reaction. This work led to a single oxygenated angular triquinane 28 from 9, and to the tricyclo[6.2.1.01,5]undecane derivative 41 from 30. An oxatricyclo[5.3.1.01,5]undecane derivative 19 was also obtained from 9.
Synthesis and evaluation of 1,1,7,7-tetramethyl-9-azajulolidine (TMAJ) as a highly active derivative of N,N-dimethylaminopyridine
Tsutsumi, Tomohiro,Saitoh, Arisa,Kasai, Tomoyo,Chu, MengYue,Karanjit, Sangita,Nakayama, Atsushi,Namba, Kosuke
supporting information, (2020/05/28)
1,1,7,7-Tetramethyl-9-azajulolidine (TMAJ), which theoretical studies have suggested as a highly active DMAP analog, was synthesized for the first time. The catalytic activity of TMAJ was confirmed by the acetylation reactions of various tert-alcohols. TMAJ showed much higher catalytic activity than DMAP and one of the highest activity levels among the conventional DMAP analogs. These experimental results were in good agreement with the previous theoretical studies.
Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy
Riggs, Jennifer R.,Elsner, Jan,Cashion, Dan,Robinson, Dale,Tehrani, Lida,Nagy, Mark,Fultz, Kimberly E.,Krishna Narla, Rama,Peng, Xiaohui,Tran, Tam,Kulkarni, Ashutosh,Bahmanyar, Sogole,Condroski, Kevin,Pagarigan, Barbra,Fenalti, Gustavo,Lebrun, Laurie,Leftheris, Katerina,Zhu, Dan,Boylan, John F.
supporting information, p. 4401 - 4410 (2019/05/17)
Triple negative breast cancer (TNBC) is an aggressive disease with high relapse rates and few treatment options. Outlined in previous publications, we identified a series of potent, dual TTK/CLK2 inhibitors with strong efficacy in TNBC xenograft models. P